Technical Analysis for DVAX - Dynavax Technologies Corporation

Grade Last Price % Change Price Change
grade D 10.97 -1.44% -0.16
DVAX closed down 1.44 percent on Tuesday, February 19, 2019, on 87 percent of normal volume.

Earnings due: Feb 26

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical DVAX trend table...

Date Alert Name Type % Chg
Feb 19 MACD Bullish Centerline Cross Bullish 0.00%
Feb 19 Bollinger Band Squeeze Range Contraction 0.00%
Feb 19 BB Squeeze Started Range Contraction 0.00%
Feb 15 Crossed Above 20 DMA Bullish -1.44%
Feb 15 Pocket Pivot Bullish Swing Setup -1.44%
Feb 14 Narrow Range Bar Range Contraction 4.08%
Feb 13 Shooting Star Candlestick Bearish 3.69%
Feb 13 Narrow Range Bar Range Contraction 3.69%
Feb 13 NR7 Range Contraction 3.69%
Feb 13 Doji - Bearish? Reversal 3.69%

Older signals for DVAX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. It develops product candidates based on the use of immunostimulatory sequences and immunoregulatory sequences. Its lead product candidate is HEPLISAV, a Phase III investigational adult hepatitis B vaccine. The company also develops DV1179, a Phase I bifunctional inhibitor of TLR7 and TLR9 for the treatment of autoimmune and inflammatory diseases; and AZD1419, a preclinical drug candidate for the treatment of asthma. It has a strategic alliance with GlaxoSmithKline to discover, develop, and commercialize TLR inhibitors; and a research collaboration and license agreement with AstraZeneca AB for the discovery and development of TLR9 agonist-based therapies for the treatment of asthma and chronic obstructive pulmonary disease. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is based in Berkeley, California.
Health Biopharmaceutical Pharmaceutical Industry Asthma Chronic Obstructive Pulmonary Disease Astrazeneca Autoimmune And Inflammatory Diseases Treatment Of Autoimmune And Inflammatory Diseases Tlr7 Tlr9
Is DVAX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 22.8
52 Week Low 7.85
Average Volume 954,179
200-Day Moving Average 12.9008
50-Day Moving Average 10.429
20-Day Moving Average 10.827
10-Day Moving Average 10.633
Average True Range 0.5044
ADX 16.08
+DI 22.5954
-DI 17.5711
Chandelier Exit (Long, 3 ATRs ) 10.7768
Chandelier Exit (Short, 3 ATRs ) 11.6732
Upper Bollinger Band 11.4856
Lower Bollinger Band 10.1684
Percent B (%b) 0.61
BandWidth 12.165882
MACD Line 0.0129
MACD Signal Line 0.0178
MACD Histogram -0.0049
Fundamentals Value
Market Cap 601.58 Million
Num Shares 54.8 Million
EPS -2.42
Price-to-Earnings (P/E) Ratio -4.53
Price-to-Sales 143.85
Price-to-Book 7.89
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.78
Resistance 3 (R3) 11.85 11.64 11.65
Resistance 2 (R2) 11.64 11.44 11.61 11.60
Resistance 1 (R1) 11.31 11.31 11.21 11.24 11.55
Pivot Point 11.10 11.10 11.05 11.07 11.10
Support 1 (S1) 10.77 10.90 10.67 10.70 10.39
Support 2 (S2) 10.56 10.77 10.53 10.34
Support 3 (S3) 10.23 10.56 10.30
Support 4 (S4) 10.16